PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals

Based: Malvern, PA
Raised: $23.2 million
Investors: Astellas Venture Management, Fletcher Spaght Associates, Hatteras Venture Partners, Johnson & Johnson Development Corporation, New Enterprise Associates.

The scoop: Just a few months after launching an early-stage study of an experimental cardiovascular drug, Malvern, PA-based PhaseBio snagged an extra $23 million in venture funds. Much of that money is being used to back a Phase IIb study of the biotech's lead drug, Glymera, an experimental diabetes drug. A third drug, called Insumera, is in a Phase I/IIstudy for Type II diabetes. The most recent entry into the clinic is known as PB1046, a VPAC2-selective vasoactive intestinal peptide agonist being studied for hypertension and congestive heart failure.

PhaseBio Pharmaceuticals

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.